{"product_id":"hfsa-virtual-board-certification-review","title":"HFSA Virtual Board Certification Review 2020","description":"\u003ch1\u003eHFSA Virtual Board Certification Review 2020\u003c\/h1\u003e\n\u003ch3\u003eGeneral Meeting Information\u003c\/h3\u003e\n\u003cdiv\u003eThe HFSA Virtual Board Certification Review 2020 will be comprised of renowned heart failure experts presenting curriculum that has been tailored to the actual ABIM examination.\u003c\/div\u003e\n\u003ch3\u003eIntended Audience\u003c\/h3\u003e\n\u003cdiv\u003eThe HFSA Virtual Board Certification Review 2020 is designed for physicians who are preparing to take the ABIM Advanced Heart Failure \u0026amp; Transplant Cardiology Board Certification Exam.\u003c\/div\u003e\n\u003ch2\u003eLearning Objectives\u003c\/h2\u003e\n\u003cdiv\u003eUpon completion of the activity, participants will demonstrate improved competence and ability to:\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003eFor the Certification Examination in Advanced Heart Failure and Transplant Cardiology:\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003eIdentify gaps in knowledge about advanced heart failure and transplant cardiology\u003c\/li\u003e\n\u003cli\u003eFocus study efforts on filling identified knowledge gaps\u003c\/li\u003e\n\u003cli\u003ePractice for the certification examination with ABIM-style multiple-choice test question\u003c\/li\u003e\n\u003cli\u003e-Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure\u003c\/li\u003e\n\u003cli\u003e-Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms\u003c\/li\u003e\n\u003cli\u003e-Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.\u003c\/li\u003e\n\u003cli\u003e-Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices\u003c\/li\u003e\n\u003cli\u003e-Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.\u003c\/li\u003e\n\u003cli\u003e-Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression\u003c\/li\u003e\n\u003cli\u003e-Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care\u003c\/li\u003e\n\u003cli\u003e-Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device\u003c\/li\u003e\n\u003cli\u003e-Concise presentations by national experts will focus on blueprint content and will be augmented by board-review type questions posed using an audience-response system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eTopics ;\u003c\/h3\u003e\n\u003cdiv\u003ePre-Course\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003e01 Heart Failure Epidemiology and Risk Factors\u003c\/li\u003e\n\u003cli\u003e02 Pathophysiology I – Cellular and Energetic Considerations\u003c\/li\u003e\n\u003cli\u003e03 Pathophysiology II – Hemodynamic, Structural, and Neurohormonal Considerations\u003c\/li\u003e\n\u003cli\u003e04 Diagnosis and Clinical Assessment\u003c\/li\u003e\n\u003cli\u003e05 Device Therapy in Heart Failure\u003c\/li\u003e\n\u003cli\u003e06 Cardio-Oncology for the HF Boards\u003c\/li\u003e\n\u003cli\u003e07 Clinico-Pathologic Correlates in Heart Failure_ Images for the Heart Failure Boards\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eDay 1\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e01 Welcome _ HFSA Introduction – Day 1\u003c\/li\u003e\n\u003cli\u003e02 Advanced Heart Failure – Defining the Phenotype and Patient Selection for Advanced Therapies\u003c\/li\u003e\n\u003cli\u003e03 Immunology – The Basics, PRA, Sensitization, Crossmatch\u003c\/li\u003e\n\u003cli\u003e04 Rejection – Cellular and Antibody Mediated\u003c\/li\u003e\n\u003cli\u003e05 Managing Immunosuppression and Drugs\u003c\/li\u003e\n\u003cli\u003e06 Heart Transplant, Clinical Outcomes and Complications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eDay 2\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eWelcome _ Introductions – Day 2\u003c\/li\u003e\n\u003cli\u003e01 Hemodynamics in HF I\u003c\/li\u003e\n\u003cli\u003e02 Hemodynamics in HF II\u003c\/li\u003e\n\u003cli\u003e03 Drug Therapy for Chronic HF I – Focus on Established Therapies\u003c\/li\u003e\n\u003cli\u003e04 Drug Therapy for Chronic HF II – Focus on Newer Therapies\u003c\/li\u003e\n\u003cli\u003e05 HFpEF – Epidemiology, Risk Factors, Diagnosis, Management (for the boards)\u003c\/li\u003e\n\u003cli\u003e06 Management of the Hospitalized HF Patient\u003c\/li\u003e\n\u003cli\u003e07 Management of Common Arrhythmias in HF (including AF)\u003c\/li\u003e\n\u003cli\u003e08 Management of Comorbidities in Heart Failure\u003c\/li\u003e\n\u003cli\u003e09 Specific Etiologies of HF I – Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)\u003c\/li\u003e\n\u003cli\u003e10 Specific Etiologies of HF II – Inherited HF Syndromes (including HCM, ARVC, and LVNC)\u003c\/li\u003e\n\u003cli\u003e11 Specific Etiologies of HF III – Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)\u003c\/li\u003e\n\u003cli\u003e12 Adult Congenital Heart Disease for the HF Specialist\u003c\/li\u003e\n\u003cli\u003e13 Q_A Panel I\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eDay 3\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eWelcome _ Introductions – Day 3\u003c\/li\u003e\n\u003cli\u003e01 Cardiogenic Shock Management\u003c\/li\u003e\n\u003cli\u003e02 MCS I – Durable MCS Devices and Outcomes\u003c\/li\u003e\n\u003cli\u003e03 MCS II – Temporary Support Devices and ECMO for the Boards\u003c\/li\u003e\n\u003cli\u003e04 MCS III – MCS Complications and Patient Management\u003c\/li\u003e\n\u003cli\u003e05 MCS IV – Troubleshooting (with HARVI)\u003c\/li\u003e\n\u003cli\u003e06 Assessment of Functional Capacity Including Cardiopulmonary Exercise Testing\u003c\/li\u003e\n\u003cli\u003e07 Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)\u003c\/li\u003e\n\u003cli\u003e08 Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)\u003c\/li\u003e\n\u003cli\u003e09 Pulmonary Hypertension\u003c\/li\u003e\n\u003cli\u003e10 Q_A Panel II\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003eRelease Date : August 2020\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954304421986,"sku":"MED-AMB00807","price":50.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/hfsa-virtual-board-certification-review-2020-1-800x445-1-510x284-1.jpg?v=1779370693","url":"https:\/\/meducourse.com\/products\/hfsa-virtual-board-certification-review","provider":"Meducourse","version":"1.0","type":"link"}